Assessment of Adherence, Effectiveness and Convenience of Rebif Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart.

Trial Profile

Assessment of Adherence, Effectiveness and Convenience of Rebif Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2015

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms SMART
  • Sponsors Merck KGaA
  • Most Recent Events

    • 23 Jun 2015 Results (follow-up of German cohort) presented at the 1st Congress of the European Academy of Neurology.
    • 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 19 Sep 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top